BrainStorm Cell Therapeutics stock delisted from Nasdaq, trades on OTCQB

BrainStorm Cell Therapeutics announced that its common stock will be delisted from the Nasdaq Capital Market due to non-compliance with Nasdaq Listing Rule 5550(b)(1). The company received approval for its shares to be quoted on the OTCQB Venture Market, a U.S. trading platform, and its shares will begin trading under the symbol BCLI on July 18, 2025.

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) has been informed by The Nasdaq Stock Market LLC that its common stock will be delisted from the Nasdaq Capital Market, effective July 18, 2025. The delisting stems from non-compliance with Nasdaq Listing Rule 5550(b)(1), which pertains to the company's minimum shareholder equity requirement. Despite this setback, BrainStorm has secured approval for its shares to be quoted on the OTCQB Venture Market, a U.S. trading platform operated by OTC Markets Group. Trading on the OTCQB is expected to commence under the same symbol, BCLI, on July 18, 2025, or as soon as possible thereafter [1].

The company's CEO, Chaim Lebovits, stated that while the delisting is a challenging outcome, it does not alter BrainStorm's core mission or its commitment to advancing NurOwn for ALS patients. The transition to OTCQB ensures continuous trading for the company's shares and allows it to focus entirely on NurOwn's development. BrainStorm remains dedicated to its ongoing scientific and clinical programs, including preparations for its pivotal Phase 3b trial under a Special Protocol Assessment (SPA) agreement with the FDA [1].

The delisting does not impact BrainStorm's business operations, its ongoing research and development efforts, or its commitment to its shareholders. The company will continue to provide updates on its progress and financial status in compliance with applicable SEC regulations [1].

BrainStorm's proprietary NurOwn platform uses autologous mesenchymal stem cells (MSCs) to produce neurotrophic factor-secreting cells (MSC-NTF cells), designed to deliver targeted biological signals that modulate neuroinflammation and promote neuroprotection. NurOwn is BrainStorm's lead investigational therapy for amyotrophic lateral sclerosis (ALS) and has received Orphan Drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) [1].

The delisting from Nasdaq signals financial challenges for BrainStorm, though operations continue as they transition to the OTCQB market. This transition typically results in reduced liquidity, decreased institutional investment, diminished analyst coverage, and potentially more challenging capital raising conditions [2][3].

References:
[1] https://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-announces-nasdaq-delisting-and-transition-to-otcqb-302508133.html
[2] https://seekingalpha.com/news/4468668-brainstorm-cell-therapeutics-to-move-from-nasdaq-to-otcqb-after-delisting-shares-down
[3] https://www.stocktitan.net/news/BCLI/brain-storm-cell-therapeutics-announces-nasdaq-delisting-and-bimi6deh5e5u.html